Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott (NYSE:ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's needs along with the company's Navitor TAVI system, which is already commercially available.
雅培(紐約證券交易所代碼:ABT)今天宣佈了首批患者手術,其研究中的經導管主動脈瓣植入(TAVI)球囊擴張系統用於治療有症狀的嚴重主動脈瓣狹窄。這種研究型雅培TAVI系統是雅培軟件制導氣球可擴展TAVI系統的第一步,旨在爲人工智能(AI)指導程序奠定基礎。一旦研究中的氣球膨脹系統完成臨床開發並獲得監管機構的批准,雅培的結構性心臟產品組合將爲醫生提供另一種滿足患者需求的TAVI管理選擇,以及該公司的Navitor TAVI系統,該系統已經上市。
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
主動脈瓣是一種心臟瓣膜,它控制富含氧氣的血液流向人體。隨着年齡的增長,鈣可能會在瓣膜中積聚並導致瓣膜變窄,這種情況被稱爲主動脈瓣狹窄,導致心臟需要更加努力地將血液泵入瓣膜。如果不加以治療,主動脈瓣狹窄會引起諸如胸痛、呼吸急促和昏厥等症狀,還會削弱心臟並危及生命。由於年齡、虛弱或患有多種其他疾病而面臨心臟直視手術風險的患者可能會受益於微創治療方案,即設備通過腿部動脈輸送到心臟。主動脈瓣狹窄仍然是最常見的原發性瓣膜疾病,其患病率隨着年齡的增長而增加,從70-80歲成年人的約2%到80歲以上的成年人的9%不等。1
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.
該研究系統是一種氣球可膨脹的TAVI設備,其工作原理是將新的心臟瓣膜壓接在放氣的氣球上。然後,裝有瓣膜的氣球通過腹股溝的動脈插入體內,然後進入心臟。一旦正確放置在狹窄的心臟瓣膜內,氣球就會充氣以擴張新瓣膜,接管患者狹窄的原生心臟瓣膜的功能。然後將氣球放氣並從體內取出。